Literature DB >> 1485660

Effect of an allergy prevention programme on incidence of atopic symptoms in infancy. A prospective study of 159 "high-risk" infants.

S Halken1, A Høst, L G Hansen, O Osterballe.   

Abstract

A total of 105 "high-risk" infants born in 1988 were studied prospectively from birth to 18 months of age. The infants were recommended breastfeeding and/or hypoallergenic formula (Nutramigen or Profylac) combined with avoidance of solid foods during the first 6 months of life. All mothers had unrestricted diet. Avoidance of daily exposure to tobacco smoke, furred pets and dust-collecting materials in the bedroom were advised. This prevention group was compared with a control group consisting of 54 identically defined "high-risk" infants born in 1985 in the same area. All infants had either severe single atopic predisposition combined with cord blood IgE > or = 0.5 KU/l or biparental atopic predisposition. The control group had unrestricted diet and was not advised about environmental factors. Apart from the prevention programme and year of birth the prevention group and the control group were comparable. The parents were highly motivated and compliance was good. The rate of participation was 97%, and 85% followed the dietary measures strictly. The cumulative prevalence of atopic symptoms was significantly lower at 18 months in the prevention group (32%), as compared with the control group (74%) (p < 0.01), due to reduced prevalence of recurrent wheezing (13% versus 37%; p < 0.01), atopic dermatitis (14% versus 31%; p < 0.01), vomiting/diarrhoea (5% versus 20%; p < 0.01) and infantile colic (9% versus 24%; p < 0.01). The cumulative prevalence of food allergy was significantly lower in the prevention group (6% versus 17%; p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1485660     DOI: 10.1111/j.1398-9995.1992.tb00680.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  15 in total

Review 1.  Strategies for prevention.

Authors:  Y Vandenplas
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 2.  Food allergy.

Authors:  R K Chandra
Journal:  Indian J Pediatr       Date:  2002-03       Impact factor: 1.967

3.  Hypo-allergenic formulae: what's in a name?

Authors:  J P Buts; S Cadranel; A Deprettere; M Scaillon; E Sokal; M Van Caillie-Bertrand; Y Vandenplas; M Vanwinckel
Journal:  Eur J Pediatr       Date:  1994-05       Impact factor: 3.183

Review 4.  Infant formulas containing hydrolysed protein for prevention of allergic disease and food allergy.

Authors:  David A Osborn; John Kh Sinn; Lisa J Jones
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

5.  Identification of core competencies for primary care of allergy patients using a modified Delphi technique.

Authors:  Joanna Wallengren
Journal:  BMC Med Educ       Date:  2011-04-04       Impact factor: 2.463

6.  Increasing breastfeeding rates in New York City, 1980-2000.

Authors:  Melanie Besculides; Karine Grigoryan; Fabienne Laraque
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

7.  Allergenicity of milk protein hydrolysate formulae in children with cow's milk allergy.

Authors:  V Ragno; P G Giampietro; G Bruno; L Businco
Journal:  Eur J Pediatr       Date:  1993-09       Impact factor: 3.183

8.  Characterization of antigens and allergens in hypo-allergenic infant formulae.

Authors:  I Görtler; R Urbanek; J Forster
Journal:  Eur J Pediatr       Date:  1995-04       Impact factor: 3.183

9.  The long-term effect of a partial whey hydrolysate formula on the prophylaxis of atopic disease.

Authors:  Y Vandenplas; B Hauser; C Van den Borre; C Clybouw; T Mahler; S Hachimi-Idrissi; L Deraeve; A Malfroot; I Dab
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

Review 10.  How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies.

Authors:  Eric L Simpson; Laura E Keck; Joanne R Chalmers; Hywel C Williams
Journal:  J Allergy Clin Immunol       Date:  2012-03-15       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.